Agilent Technologies announced that the U.S. Food and Drug Administration has approved its PD‑L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic for patients with esophageal or gastroesophageal junction carcinoma who may be eligible for treatment with Merck’s KEYTRUDA® (pembrolizumab). The approval, granted on March 26, 2026, makes the test the only FDA‑approved companion diagnostic for this indication, giving Agilent a unique foothold in the rapidly expanding immuno‑oncology diagnostics market.
The PD‑L1 IHC 22C3 pharmDx is part of Agilent’s broader portfolio of companion diagnostics that partner with pharmaceutical companies to identify patients likely to benefit from targeted therapies. By adding this test, Agilent expands its presence in the oncology space and creates a new revenue stream tied to the adoption of KEYTRUDA in esophageal and GEJ cancers, strengthening its competitive position against rivals such as Roche and Thermo Fisher.
Agilent’s Q1 fiscal 2026 results, released shortly before the approval announcement, showed revenue of $1.80 billion, a 7.0% year‑over‑year increase, and non‑GAAP earnings per share of $1.36, up 4% from the same quarter a year earlier. The company’s GAAP net income fell 4% versus Q1 2025, and revenue missed analyst consensus of $1.81 billion while EPS of $1.36 fell slightly below the $1.37 estimate. Management attributed the shortfall to a major U.S. snowstorm that impacted operations in the final week of the quarter, noting that on a normalized basis the results would have exceeded guidance. In the preceding quarter, Q4 FY2025, Agilent reported revenue of $1.86 billion, up 9.4% YoY, and non‑GAAP EPS of $1.59, beating expectations.
Segment‑level data from Q1 FY2026 illustrate the drivers behind the top‑line growth: the Life Sciences and Diagnostics Markets Group generated $679 million in revenue, up 5% reported and 3% core YoY; the Agilent CrossLab Group delivered $758 million, up 9% reported and 6% core YoY; and the Applied Markets Group posted $361 million, up 7% reported and 4% core YoY. These gains reflect strong demand in core diagnostic and analytical segments, offsetting headwinds in legacy product lines.
Padraig McDonnell, Agilent’s President and CEO, said the company had “executed well in a healthy—albeit dynamic—market environment that included navigating the impact of a major U.S. snowstorm during the last week of the quarter. On a normalized basis, excluding the weather‑related impact, first‑quarter results would have exceeded the midpoint of our guidance.” Nina Green, Vice President and General Manager of Agilent’s Clinical Diagnostics Division, added that the approval “reflects Agilent’s long‑standing industry partnership in companion diagnostics. We are proud to enable pathologists to identify patients with EOC who may benefit from immunotherapy. As the first immuno‑oncology approval for this disease, this milestone underscores our commitment to advancing precision medicine and expanding access to innovative cancer treatments worldwide.”
The approval reinforces Agilent’s strategy to deepen its oncology diagnostics portfolio. The company has recently announced plans to acquire Biocare Medical for $950 million to broaden its pathology and cancer diagnostics capabilities, and it has launched Agilent Advanced Therapeutics to consolidate its contract manufacturing organization services. These moves, combined with the new FDA approval, position Agilent to capture a larger share of the oncology testing market and to capitalize on the growing demand for precision oncology solutions.
The competitive landscape remains crowded, with Roche’s VENTANA PD‑L1 assays (SP263 and SP142) and Thermo Fisher’s PD‑L1 antibodies and kits also targeting similar indications. However, Agilent’s exclusive approval for esophageal and GEJ cancers gives it a distinct advantage, potentially translating into higher market penetration and stronger pricing power in this niche segment.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.